L.TO vs. CORT
L.TO (Loblaw Companies Limited) and CORT (Corcept Therapeutics Incorporated) are both stocks. L.TO operates in Grocery Stores (Consumer Defensive), while CORT operates in Biotechnology (Healthcare). Over the past 10 years, L.TO returned 26.65%/yr vs 32.65%/yr for CORT. At a 0.06 correlation, their price movements are largely independent.
Performance
L.TO vs. CORT - Performance Comparison
Loading charts...
Different Trading Currencies
L.TO is traded in CAD, while CORT is traded in USD. To make them comparable, the CORT values have been converted to CAD using the latest available exchange rates.
Returns By Period
In the year-to-date period, L.TO achieves a 2.62% return, which is significantly lower than CORT's 137.07% return. Over the past 10 years, L.TO has underperformed CORT with an annualized return of 26.65%, while CORT has yielded a comparatively higher 32.65% annualized return.
L.TO
- 1D
- -1.11%
- 1M
- 3.42%
- YTD
- 2.62%
- 6M
- 2.89%
- 1Y
- 15.10%
- 3Y*
- 34.35%
- 5Y*
- 33.11%
- 10Y*
- 26.65%
CORT
- 1D
- 0.28%
- 1M
- 36.19%
- YTD
- 137.07%
- 6M
- -3.74%
- 1Y
- 15.57%
- 3Y*
- 57.83%
- 5Y*
- 32.75%
- 10Y*
- 32.65%
L.TO vs. CORT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
L.TO Loblaw Companies Limited | 2.62% | 34.69% | 54.55% | 13.67% | 21.98% | 76.92% | 1.32% | 17.76% | 51.51% | 4.10% |
CORT Corcept Therapeutics Incorporated | 137.07% | -34.09% | 68.28% | 56.12% | 9.08% | -24.35% | 111.07% | -13.16% | -19.80% | 131.92% |
Correlation
The correlation between L.TO and CORT is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.07 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.03 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Jul 20, 2006 | 0.06 |
Fundamentals
L.TO:
CA$74.67B
CORT:
$8.32B
L.TO:
CA$3.72
CORT:
$0.41
L.TO:
17.05
CORT:
194.37
L.TO:
0.73
CORT:
12.03
L.TO:
6.85
CORT:
13.05
L.TO:
CA$64.25B
CORT:
$769.10M
L.TO:
CA$19.91B
CORT:
$755.64M
L.TO:
CA$7.21B
CORT:
$3.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
L.TO vs. CORT — Risk / Return Rank
L.TO
CORT
L.TO vs. CORT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Loblaw Companies Limited (L.TO) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| L.TO | CORT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.51 | ||
| Sortino ratioReturn per unit of downside risk | +0.27 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.17 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 1.04 | 0.24 | +0.80 |
| Martin ratioReturn relative to average drawdown | 2.43 | 0.44 | +2.00 |
Loading charts...
Drawdowns
L.TO vs. CORT - Drawdown Comparison
The maximum L.TO drawdown since its inception was -44.67%, smaller than the maximum CORT drawdown of -95.16%. Use the drawdown chart below to compare losses from any high point for L.TO and CORT.
Loading charts...
Drawdown Indicators
| L.TO | CORT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -44.67% | -95.16% | +50.49% |
Max Drawdown (1Y)Largest decline over 1 year | -14.53% | -65.20% | +50.67% |
Max Drawdown (3Y)Largest decline over 3 years | -14.53% | -73.18% | +58.65% |
Max Drawdown (5Y)Largest decline over 5 years | -14.53% | -73.18% | +58.65% |
Max Drawdown (10Y)Largest decline over 10 years | -18.54% | -73.18% | +54.64% |
Current DrawdownCurrent decline from peak | -8.06% | -30.87% | +22.81% |
Average DrawdownAverage peak-to-trough decline | -7.05% | -55.36% | +48.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.22% | 35.82% | -29.60% |
Volatility
L.TO vs. CORT - Volatility Comparison
The current volatility for Loblaw Companies Limited (L.TO) is 6.47%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 13.34%. This indicates that L.TO experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| L.TO | CORT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.47% | 13.34% | -6.87% |
Volatility (6M)Calculated over the trailing 6-month period | 16.19% | 84.98% | -68.79% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.21% | 77.24% | -56.03% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.94% | 74.93% | -55.99% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.39% | 67.73% | -47.34% |
Dividends
L.TO vs. CORT - Dividend Comparison
L.TO's dividend yield for the trailing twelve months is around 0.91%, while CORT has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CORT Corcept Therapeutics Incorporated | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
L.TO Loblaw Companies Limited | 0.91% | 2.19% | 4.20% | 5.43% | 5.28% | 5.40% | 8.15% | 7.40% | 6.45% | 7.84% | 7.27% | 7.61% |
Financials
L.TO vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between Loblaw Companies Limited and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
L.TO vs. CORT - Profitability Comparison
L.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Loblaw Companies Limited reported a gross profit of 4.54B and revenue of 14.48B. Therefore, the gross margin over that period was 31.3%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
L.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Loblaw Companies Limited reported an operating income of 1.01B and revenue of 14.48B, resulting in an operating margin of 7.0%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
L.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Loblaw Companies Limited reported a net income of 594.00M and revenue of 14.48B, resulting in a net margin of 4.1%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
Frequently Asked Questions
L.TO and CORT have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for L.TO and CORT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer